ClearPoint Neuro price target lowered to $11 from $15 at Lake Street

Lake Street lowered the firm’s price target on ClearPoint Neuro to $11 from $15 and keeps a Buy rating on the shares, citing a revenue forecast revision and continued marketwide multiple compression for its lowered target. The firm argues that all three primary growth drivers “remain in play” and while it expects ClearPoint to “pursue them in a more cost-effective manner,” it does not expect this to change the long-term potential.